Spyglass Pharma, Inc. (SGP) Stock Price & Analysis
Spyglass Pharma, Inc. (SGP) fell 2.93% to USD 18.19 as of June 10, 2026 at 04:35 UTC, according to Nexqual real-time market data.
SGP last closed at USD 18.74; the session ranged USD 18.18–19.28 on volume of 70,136 shares. Market capitalization is $608.15M, with a 52-week range of USD 17.6–32.44 (NMS). Source: Nexqual, June 10, 2026 at 04:35 UTC.
Key Statistics (as of June 10, 2026 at 04:35 UTC)
| Price | USD 18.19 |
|---|---|
| Change | ▼ 2.93% (down) |
| Previous Close | USD 18.74 |
| Open | USD 18.9 |
| Day Range | USD 18.18 – 19.28 |
| 52-Week Range | USD 17.6 – 32.44 |
| Volume | 70,136 shares |
| Market Cap | $608.15M |
| Exchange | NMS |
Technical Analysis (SGP)
Nexqual's technical model rates SGP "SELL" based on 1 bullish and 5 bearish signals across 84 daily candles, as of June 10, 2026 at 04:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.77 (neutral) |
| vs SMA50 | Below (USD 22.57) |
| MACD | -1.35 (negative) |
Analyst Ratings (SGP)
Wall Street analysts rate SGP "Strong Buy" based on 5 analysts, with a mean price target of USD 45 (range USD 37–62), per Nexqual as of June 10, 2026 at 04:35 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 45 |
| High Target | USD 62 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (SGP)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.69 vs est -0.36 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:35 UTC.
Financials & Fundamentals (SGP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -67.70% |
| Debt / Equity | 1.5 |
| Current Ratio | 12.67 |
| Total Cash | $107.44M |
| Total Debt | $1.58M |
| Free Cash Flow | $-22.24M |
Source: Nexqual, June 10, 2026 at 04:35 UTC.
Financial Health Score (SGP)
Nexqual rates Spyglass Pharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:35 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $107M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$33M |
| Efficiency | Critical — ROE -68%, ROA -37.2% |
Ownership (SGP)
| Insider Ownership | +4.28% |
|---|---|
| Institutional Ownership | +92.28% |
| Shares Outstanding | 33.43M |
| Float | 6.48M |
| Short % of Float | +10.32% |
Source: Nexqual, June 10, 2026 at 04:35 UTC.
Leadership (SGP)
Spyglass Pharma, Inc. is led by Patrick H. Mooney (age 51), CEO & Director, per Nexqual as of June 10, 2026 at 04:35 UTC.
| CEO & Director | Patrick H. Mooney (age 51) |
|---|---|
| Co-Founder, President, Chief Medical Officer & Executive Chairman | Malik Y. Kahook (age 50) |
| Co-founder & Chief Technology Advisor | Glenn Sussman (age 61) |
| Chief Financial Officer | Jean-Frederic Viret (age 59) |
| Chief Operating Officer | James Robert Dennewill (age 44) |
Major Backers & Investors (SGP)
Notable institutional backers of Spyglass Pharma, Inc. include RA Capital Management, L.P., NEA Management Company, LLC, Sands Capital Alternatives, LLC, according to Nexqual as of June 10, 2026 at 04:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 23.99% |
| NEA Management Company, LLC | 22.11% |
| Sands Capital Alternatives, LLC | 7.48% |
| Samsara BioCapital, LLC | 6.31% |
| JPMorgan | 2.92% |
| Price (T.Rowe) Associates Inc | 2.42% |
| Vestal Point Capital, LP | 1.99% |
| Deerfield Management Company, L.P | 1.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.57% |
Source: Nexqual, June 10, 2026 at 04:35 UTC.
From Spyglass Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
- The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
- It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost.
- SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | USD 8.25 | ▲ 0.36% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| KG | Kestrel Group, Ltd. | USD 11.78 | ▼ 1.26% |
| SLE | Super League Enterprise, Inc. | USD 3.17 | ▼ 4.8% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:35 UTC. This page is informational and not investment advice.